AstraZeneca Pharma (India) Today
| ASTRAZEN | 8,416 64.10 0.76% |
PerformanceGood
| Odds Of DistressVery Small
|
AstraZeneca Pharma is trading at 8416.35 as of the 25th of March 2025, a 0.76 percent decrease since the beginning of the trading day. The stock's lowest day price was 8368.6. AstraZeneca Pharma has a very small chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
AstraZeneca Pharma is entity of India. It is traded as Stock on NSE exchange. The company has 25 M outstanding shares. More on AstraZeneca Pharma India
Moving together with AstraZeneca Stock
Moving against AstraZeneca Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
AstraZeneca Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. AstraZeneca Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding AstraZeneca Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
AstraZeneca Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to AstraZeneca Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsAstraZeneca Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AstraZeneca Pharma's financial leverage. It provides some insight into what part of AstraZeneca Pharma's total assets is financed by creditors.
| |||||
AstraZeneca Pharma India (ASTRAZEN) is traded on National Stock Exchange of India in India and employs 940 people. AstraZeneca Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 212.28 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AstraZeneca Pharma's market, we take the total number of its shares issued and multiply it by AstraZeneca Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AstraZeneca Pharma India operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 25 M outstanding shares.
AstraZeneca Pharma India has accumulated about 4.98 B in cash with 278.7 M of positive cash flow from operations.
Check AstraZeneca Pharma Probability Of Bankruptcy
Ownership AllocationAstraZeneca Pharma holds a total of 25 Million outstanding shares. AstraZeneca Pharma India shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 85.57 percent of AstraZeneca Pharma India outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AstraZeneca Ownership Details
AstraZeneca Pharma India Risk Profiles
Although AstraZeneca Pharma's alpha and beta are two of the key measurements used to evaluate AstraZeneca Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.68 | |||
| Semi Deviation | 1.4 | |||
| Standard Deviation | 2.72 | |||
| Variance | 7.39 |
AstraZeneca Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in AstraZeneca Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
AstraZeneca Pharma Corporate Directors
| Rajesh Marwaha | CFO Director | Profile | |
| Bhavana Agrawal | Additional Director | Profile | |
| K Shenoy | Director Regulatory | Profile | |
| Ramesh Venkatapathi | Director Services | Profile |
Other Information on Investing in AstraZeneca Stock
AstraZeneca Pharma financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca Pharma security.